Test Price
2,800 AED✅ Home Collection Available
ANKRD11 Gene Genetic Test for KBG Syndrome
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑Certified Next‑Generation Sequencing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary telephonic post‑test result interpretation by a genetic counsellor.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The ANKRD11 Genetic Test analyses the entire coding region of the ANKRD11 gene using next‑generation sequencing, definitively identifying pathogenic variants responsible for KBG syndrome—a rare disorder marked by dysmorphic features, intellectual disability, and skeletal anomalies. This molecular assay is the gold standard for confirmatory diagnosis in individuals with clinical suspicion of KBG syndrome.
| Feature | Our Test (ANKRD11 NGS) | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Technology | NGS (Illumina‑based, parallel sequencing) | Sanger sequencing |
| Detection Range | SNVs, indels, small CNVs – full coding region | Targeted hotspot or single variant only |
| Diagnostic Sensitivity | 99.9% analytical sensitivity | ~98% for known single alleles |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Cost (AED) | 2,800 | 2,500–3,000 |
Physician Insight & Safety Protocols
“The ANKRD11 NGS test provides precise molecular confirmation of KBG syndrome, yet a negative result does not exclude other genetic aetiologies. All findings must be interpreted within the complete clinical and family context, ideally during a dedicated post‑test genetic counselling session. Do not alter any medical therapy solely based on genetic results without consulting the managing paediatrician.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Advisory
This test should not be used as a standalone screening instrument. It is indicated only when there is a documented clinical suspicion of KBG syndrome based on dysmorphology, developmental delay, intellectual disability, or skeletal findings. A positive result requires confirmation through segregation analysis and multidisciplinary clinical correlation.
Exclusion Criteria & Emergency Red Flags
- Not to be used as the sole diagnostic tool in the absence of clinical suspicion of KBG syndrome.
- Patients unable to provide informed consent; for minors, parental or guardian consent is mandatory per UAE Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Recent blood transfusion (within two weeks) may compromise DNA quality; postpone collection if possible.
- Seek emergency care immediately if new‑onset seizures, sudden loss of developmental milestones, or severe obtundation occur after test.
Patient FAQ & Clinical Guidance
1. What is the accuracy of the ANKRD11 NGS test for KBG syndrome?
This NGS test achieves 99.9% analytical sensitivity and specificity for detecting single nucleotide variants and small deletions or duplications in the ANKRD11 gene. The full coding region is analysed using Illumina‑based parallel sequencing in a DHA‑accredited laboratory, ensuring results align with global genomic databases.
2. How long do results take and how are they reported?
Results are typically issued within three to four weeks and include a comprehensive clinical report with variant classification according to ACMG guidelines. Reports are delivered via encrypted email or the patient portal, and a complimentary telephonic genetic counselling session is provided to discuss findings and recommended next steps.
3. Does insurance cover this genetic test in the UAE?
We offer direct insurance billing verification via WhatsApp at +971 54 548 8731. Many UAE insurers cover medically necessary genetic testing when prescribed by a specialist. Please provide a copy of the physician referral and your insurance card for real‑time eligibility confirmation.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This laboratory service is DHA‑accredited (Facility License: 1143), operates under ISO 9001:2015, and strictly adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing and patient consent procedures comply with Federal Decree‑Law No. 4 of 2016 on Medical Liability. Sample handling and data processing meet DHA and MOHAP standards for genetic information security.
Clinical & Logistical Metadata
| Test Name | ANKRD11 Gene Genetic Test for KBG Syndrome |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina‑based, full coding region analysis |
| ICD-10-CM Code | Q87.89 (Other specified congenital malformation syndromes) |
| LOINC Code | 81263-6 (Genetic analysis of ANKRD11 gene) |
| DHA Facility License & Laboratory Address | Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians